Use of percentage change in clinical trials

As discussed here, the percent change from baseline used to define “response” in solid tumor oncology trials is clinically inappropriate and unintuitive to many of us physicians. A tumor that grows from 1 cm to 2 cm in max diameter is very different than one that grows from 5 cm to 10 cm. Our clinical response to the latter will often be very different than the former even though both correspond to “100% increase from baseline”.

3 Likes